Our goal is to follow the linear time course of predisposition, initiation, early stages and advanced disease and to dissect the molecular mechanisms triggered at each stage and to follow the multidimentional interactions at various levels in a systems biology approach to be able to better do risk estimation, prognostication and prediction.

To reach these goals we have divided our research into 7 activities:

Gene environment interaction in breast cancer risk
Tumor initiation and early diagnosis
Tumor progression and metastasis
Prediction of treatment response and targeted therapy
Integrated approaches
Functional validation
Biostatistical challenges and approaches

[463 visits]

Go back

Print this page

E-mail this page

Situated at:

Radiumhospitalet

News & events

Gordon Research Conference awards to Haugsten and Zakrzewska
May 22, 2012

Institute Seminar - Wednesday May 23rd
Giske Ursin
May 22, 2012

Understanding breast cancer
Landscape of cancer genes and mutational processes in breast cancer
May 21, 2012

Untangling the development of breast cancer
Researchers announce the first comprehensive genome studies of the evolution of 21 breast cancers
May 18, 2012

Presentation of prestigious research project
Actionable Targets in Cancer Metastasis (MetAction) – from Bed to Bench to Byte to Bedside
May 16, 2012

More news

Latest publications

Dept of Genetics

Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2012)
Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing
PLoS One, 7 (4), e34150
PubMed 22529906

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC Group, Co-chairs, Caldas C, Aparicio S, Writing committee, Curtis C, Shah SP, Caldas C, Aparicio S et al.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Nature (in press)
PubMed 22522925

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012)
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
J Clin Oncol, 30 (15), 1755-62
PubMed 22473155

More publications